SCHEMBL17491420

SCHEMBL17491420

O=C(Nc1cc(-c2cnco2)cc(C(F)(F)F)c1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.65
▸ RAB9A P51151 3/20 0.65
▸ KDM4E B2RXH2 2/20 0.65
▸ PKM P14618 2/20 0.65
▸ LMNA P02545 2/20 0.65
▸ ALDH1A1 P00352 1/20 0.65
▸ P2RX1 P51575 3/20 0.62
▸ IMPDH2 P12268 1/20 0.55
▸ TRPA1 O75762 2/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ KCNK3 O14649 1/20 0.48
▸ NR2E1 Q9Y466 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ RHOA P61586 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ JUN P05412 1/20 0.45
▸ NFKB1 P19838 1/20 0.45
▸ NFKB2 Q00653 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17491404 0.90 MEN1 (0.61) NPC1RAB9AKDM4EPKMLMNA
SCHEMBL17491467 0.89 KDM4E (0.66) NPC1RAB9AKDM4EPKMLMNA
SCHEMBL17491475 0.88 P2RX1 (0.51) NPC1RAB9AKDM4EPKMLMNA
SCHEMBL17491447 0.86 IMPDH2 (0.51) NPC1RAB9AKDM4EPKMLMNA
SCHEMBL17491482 0.86 CES1 (0.47) NPC1RAB9AKDM4EPKMLMNA
SCHEMBL17491499 0.85 P2RX1 (0.53) NPC1RAB9AKDM4EPKMLMNA
SCHEMBL17491537 0.83 TRPA1 (0.60) NPC1RAB9AKDM4ELMNAALDH1A1
SCHEMBL17491415 0.82 BRAF (0.47) NPC1RAB9AKDM4EPKMLMNA
SCHEMBL17491408 0.80 EGFR (0.43) NPC1RAB9AKDM4EPKMLMNA
SCHEMBL17491518 0.79 AAK1 (0.46) IMPDH2RHOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982670-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-11-07 — — EP disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-20160052897-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-25 — — US disclosed
EP-2982670-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
EP-2982670-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052897-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 NPC1 498/4885RAB9A 2187/4885KDM4E 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback